Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Zyga's sacroiliac joint fusion system

This article was originally published in Clinica

Executive Summary

SImmetry, a minimally-invasive sacroiliac joint fusion system developed by Zyga Technology, has received 510(k) clearance from the US FDA. Dysfunction of the sacroiliac joint in the pelvis is thought to be responsible for around 30% of cases of low back pain. Eden Prairie, Minnesota-based Zyga’s system is intended to treat conditions including degenerative sacroiliitis and sacroiliac joint disruptions, and consists of a range of bone screws and associated instruments that are designed to transfix the sacrum and ilium and allow bony fusion. Other options for sacroiliac joint dysfunction include periodic injections, or open surgery to fuse the joint, which can lead to complications and poor outcomes.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel